Compare · BRKR vs QTRX
BRKR vs QTRX
Side-by-side comparison of Bruker Corporation (BRKR) and Quanterix Corporation (QTRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and QTRX operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $8.66B, about 65.6x QTRX ($131.9M).
- BRKR has been more active in the news (19 items in the past 4 weeks vs 13 for QTRX).
- BRKR has more recent analyst coverage (22 ratings vs 13 for QTRX).
- Company
- Bruker Corporation
- Quanterix Corporation
- Price
- $56.86-0.22%
- $2.79-0.36%
- Market cap
- $8.66B
- $131.9M
- 1M return
- -
- -23.77%
- 1Y return
- -
- -40.51%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 19
- 13
- Recent ratings
- 22
- 13
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Quanterix Corporation
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Latest BRKR
- Chief Accounting Officer Bures Thomas was granted 4,035 shares, increasing direct ownership by 126% to 7,233 units (SEC Form 4)
- President BMID Group Pusch Wolfgang sold $197,614 worth of shares (3,473 units at $56.90) and was granted 3,120 shares, decreasing direct ownership by 3% to 9,801 units (SEC Form 4)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N was granted 15,794 shares and covered exercise/tax liability with 2,724 shares, increasing direct ownership by 13% to 111,354 units (SEC Form 4) to cover taxes
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19, sold $115,200 worth of shares (2,000 units at $57.60) as part of a pre-agreed trading plan, was granted 14,443 shares and covered exercise/tax liability with 2,984 shares, increasing direct ownership by 9% to 134,806 units (SEC Form 4) (for tax liability)
- PRESIDENT & CEO Laukien Frank H was granted 29,463 shares and covered exercise/tax liability with 4,760 shares, increasing direct ownership by 0.06% to 38,507,043 units (SEC Form 4) to cover withholding tax
- PRESIDENT CALID Srega Juergen was granted 16,898 shares, increasing direct ownership by 11% to 174,625 units (SEC Form 4)
- PRES. & CEO, BRUKER BEST Prause Burkhard was granted 3,303 shares, increasing direct ownership by 13% to 28,461 units (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark covered exercise/tax liability with 1,619 shares, decreasing direct ownership by 1% to 123,347 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT & CEO Laukien Frank H covered exercise/tax liability with 4,838 shares, decreasing direct ownership by 0.01% to 38,482,340 units (SEC Form 4) (tax withholding)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N covered exercise/tax liability with 1,410 shares, decreasing direct ownership by 1% to 98,284 units (SEC Form 4) (for tax liability)
Latest QTRX
- Director Elliott Jeffrey Thomas converted options into 3,955 shares, increasing direct ownership by 35% to 15,345 units (SEC Form 4)
- SEC Form 3 filed by new insider Gute James Edward Jr.
- Director Donnelly William P converted options into 2,802 shares, increasing direct ownership by 2% to 162,401 units (SEC Form 4)
- Chief Technology Officer Miller Michael Francis converted options into 1,558 shares and covered exercise/tax liability with 467 shares, increasing direct ownership by 3% to 37,250 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Quanterix Corporation
- SEC Form 10-Q filed by Quanterix Corporation
- Quanterix Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Quanterix Names Jim Gute Chief Commercial Officer
- Quanterix Releases Financial Results for the Second Quarter of 2026
- SEC Form SCHEDULE 13G filed by Quanterix Corporation